InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
首席财务官已披露买入
1
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-39.6%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the complete record of transactions filed by Hamm John M., 首席财务官. Insider active across 1 company, notably Cumberland Pharmaceuticals INC. In total, 5 disclosures have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €8k. History available since 23 November 2021. The latest transaction was filed on 16 March 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Hamm John M.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报5 总计
5,930 股@ US$5.4631.7% 占其流量Common StockSEC:0001628280-25-013513:0
445 股@ US$1.810.8% 占其流量Common StockSEC:0001214659-24-005208:0
352 股@ US$1.670.6% 占其流量Common StockSEC:0001214659-23-016106:0
20,000 股@ US$2.5954.7% 占其流量Common StockSEC:0001209191-22-026140:0
3,800 股@ US$2.359.2% 占其流量Common StockSEC:0001209191-21-067905:0
标准退出：2022年2月21日 (T+90)
5 条申报中的 5 条
About Hamm John M.
John M. Hamm is the Chief Financial Officer of CUMBERLAND PHARMACEUTICALS INC. He is responsible for the financial management of the company, including financial planning and financial reporting. Hamm plays a crucial role in Cumberland Pharmaceuticals' financial strategy, contributing to its stability and growth.
